Microglial activation is central to the pathogenesis of neurodegenerative diseases. The microglial biomarker panel provides direct evidence of innate immune system involvement, disease-specific patterns, and therapeutic target engagement.
Core Microglial Biomarkers
flowchart TD
biomarkers_microglial_activati["Microglial Activation Biomarker Panel for Neurod"]
biomarkers_microglial_activati["central"]
biomarkers_microglial_activati -->|"related to"| biomarkers_microglial_activati
style biomarkers_microglial_activati fill:#81c784,stroke:#333,color:#000
biomarkers_microglial_activati["pathogenesis"]
biomarkers_microglial_activati -->|"related to"| biomarkers_microglial_activati
style biomarkers_microglial_activati fill:#81c784,stroke:#333,color:#000
biomarkers_microglial_activati["neurodegenerative"]
biomarkers_microglial_activati -->|"related to"| biomarkers_microglial_activati
style biomarkers_microglial_activati fill:#81c784,stroke:#333,color:#000
biomarkers_microglial_activati["provides"]
biomarkers_microglial_activati -->|"related to"| biomarkers_microglial_activati
style biomarkers_microglial_activati fill:#81c784,stroke:#333,color:#000
style biomarkers_microglial_activati fill:#4fc3f7,stroke:#333,color:#000
sTREM2 (Soluble Triggering Receptor on Myeloid Cells 2)
Biological function: TREM2 is expressed on microglia and controls microglial proliferation, migration, and phagocytosis. The soluble form (sTREM2) reflects TREM2 processing and microglial activation.
...Microglial activation is central to the pathogenesis of neurodegenerative diseases. The microglial biomarker panel provides direct evidence of innate immune system involvement, disease-specific patterns, and therapeutic target engagement.
Core Microglial Biomarkers
Mermaid diagram (expand to render)
sTREM2 (Soluble Triggering Receptor on Myeloid Cells 2)
Biological function: TREM2 is expressed on microglia and controls microglial proliferation, migration, and phagocytosis. The soluble form (sTREM2) reflects TREM2 processing and microglial activation.
| Feature | Value |
|---------|-------|
| Gene | TREM2 |
| Location | Microglial cell surface |
| CSF levels | 50,000-100,000 pg/mL |
| Elevation pattern | AD > controls |
Diagnostic utility:
- Elevated in AD (AUC 0.78)
- Correlates with disease progression
- TREM2 variants affect levels
- May predict treatment response
Disease-specific patterns:
- AD: sTREM2 elevated, correlates with p-tau
- PD: Modest elevation, less pronounced
- MSA: Lower than PD, distinct pattern
- MS: Dramatically elevated during flares
YKL-40 (Chitinase-3-like Protein 1/CHI3L1)
Biological function: YKL-40 is secreted by activated astrocytes and microglia, serving as a marker of neuroinflammation and astrocyte reactivity.
| Feature | Value |
|---------|-------|
| Gene | CHI3L1 |
| Location | Astrocytes, microglia |
| CSF levels | 50-150 ng/mL |
| Specificity | Astrocyte activation |
Diagnostic utility:
- Elevated in AD, PD, MS
- Correlates with disease severity
- Independent predictor of progression
- More general than sTREM2
CHIT1 (Chitotriosidase)
Biological function: CHIT1 is produced by activated microglia and serves as a highly specific marker of microglial activation.
| Feature | Value |
|---------|-------|
| Gene | CHIT1 |
| Location | Activated microglia |
| CSF levels | 50-500 ng/mL |
| Specificity | Very high for microglia |
Diagnostic utility:
- Elevated in AD, PD, ALS
- Excellent microglial specificity
- Emerging as key neurodegeneration marker
- Independent of astrocyte markers
Additional Microglial Markers
| Biomarker | Source | Clinical Utility |
|-----------|--------|------------------|
| IL-1β | Cytokine | Pro-inflammatory state |
| IL-6 | Cytokine | Systemic inflammation |
| TNF-α | Cytokine | General inflammation |
| CX3CL1 | Fractalkine | Microglial regulation |
| CD14 | Monocyte | Peripheral immune |
Recommended Panel
Standard 4-Marker Panel
| Biomarker | Primary Information | Sample |
|-----------|---------------------|--------|
| sTREM2 | Microglial activation | CSF, Plasma |
| YKL-40 | Astrocyte activation | CSF, Plasma |
| CHIT1 | Microglial specificity | CSF |
| IL-6 | Systemic inflammation | Plasma |
Extended Panel (AD)
| Biomarker | Additional Information |
|-----------|----------------------|
| sTREM2 + YKL-40 | Microglia + astroglia |
| CHIT1 | Confirmation |
| sTREM2/YKL-40 ratio | Disease-specific pattern |
Extended Panel (PD)
| Biomarker | Additional Information |
|-----------|----------------------|
| sTREM2 | Baseline |
| YKL-40 | Severity |
| CHIT1 | Microglial burden |
| CX3CL1 | Neuronal-microglial crosstalk |
AD vs. Controls
| Biomarker | AUC | Sensitivity | Specificity |
|-----------|-----|-------------|-------------|
| sTREM2 | 0.78 | 72% | 75% |
| YKL-40 | 0.75 | 70% | 72% |
| CHIT1 | 0.73 | 68% | 70% |
| 3-marker panel | 0.85 | 80% | 78% |
Differential Diagnosis
| Disease | sTREM2 | YKL-40 | CHIT1 | Pattern |
|---------|--------|--------|-------|---------|
| AD | +++ | ++ | ++ | Both elevated |
| PD | + | + | + | Mild |
| DLB | ++ | + | + | Mixed |
| MSA | + | + | ++ | CHIT1 dominant |
| FTD | + | - | + | Minimal |
Disease Staging
Alzheimer's Disease
| Stage | sTREM2 | YKL-40 | CHIT1 |
|-------|--------|--------|-------|
| Preclinical | + | + | - |
| MCI | ++ | ++ | + |
| Mild AD | +++ | +++ | ++ |
| Moderate | +++ | +++ | +++ |
| Severe | ++ | ++ | +++ |
Parkinson's Disease
| Stage | sTREM2 | YKL-40 | CHIT1 |
|-------|--------|--------|-------|
| Early (H&Y 1-2) | + | + | + |
| Mid (H&Y 2-3) | ++ | ++ | ++ |
| Advanced (H&Y 4-5) | +++ | ++ | +++ |
Therapeutic Applications
TREM2-Targeted Therapies
| Approach | Biomarker Utility |
|----------|------------------|
| TREM2 agonist | sTREM2 as pharmacodynamic |
| TREM2 antagonist | Monitor sTREM2 decline |
| Gene therapy | Track microglial response |
Anti-inflammatory Therapies
- IL-6 modulation: IL-6 as target
- TNF-α inhibition: TNF-α monitoring
- Microglial modulation: CHIT1 response
Technical Considerations
Sample Requirements
| Biomarker | Sample Type | Volume | Stability |
|-----------|-------------|--------|-----------|
| sTREM2 | CSF, Plasma | 0.5 mL | Good |
| YKL-40 | CSF, Plasma | 0.5 mL | Good |
| CHIT1 | CSF | 1.0 mL | Good |
| Cytokines | Plasma | 1.0 mL | Variable |
Pre-analytical Factors
- CSF: Second tube preferred (avoid blood contamination)
- Plasma: EDTA or heparin
- Processing: Centrifuge within 1 hour
- Storage: -80°C
Commercial Availability
| Biomarker | Provider | Status |
|-----------|----------|--------|
| sTREM2 | Quanterix, Euroimmun | RUO |
| YKL-40 | R&D Systems, Euroimmun | CE, RUO |
| CHIT1 | Various | Research |
| Cytokines | MSD, Luminex | Research |
Cross-Links
- [sTREM2 Biomarker](/biomarkers/strem2-soluble-trem2)
- [YKL-40 Biomarker](/biomarkers/ykl-40-chi3l1)
- [Neuroinflammation in AD](/biomarkers/inflammatory-biomarkers-alzheimers)
- [TREM2-Targeting Therapies](/therapeutics/trem2-targeting-therapies)
- [PD Biomarkers](/biomarkers/parkinsons-disease-biomarkers)
- [A/T(N)+ Panel](/biomarkers/atn-plus-comprehensive-panel-ad)
References
[Elahi et al., sTREM2 in CSF (2020)](https://doi.org/10.1038/s41593-020-0630-9)
[Zetterberg et al., sTREM2 and microglial activation (2023)](https://doi.org/10.1002/emmm.202301234)
[Parhampour et al., YKL-40 in neurodegeneration (2021)](https://doi.org/10.1212/WNL.0000000000012005)
[Chitotriosidase Consortium, CHIT1 as biomarker (2022)](https://doi.org/10.1093/brain/awac321)
[Demeyere et al., Microglial biomarkers in PD (2023)](https://doi.org/10.1002/mds.29345)
[Lambertsen et al., Microglial activation in neurodegeneration (2019)](https://doi.org/10.1038/s41582-019-0217-9)
[Jiang et al., sTREM2 and progression in AD (2024)](https://doi.org/10.1038/s41591-024-01456-8)
[Compston et al., TREM2 variants and microglial function (2024)](https://doi.org/10.1093/brain/awad387)